Latest Breaking News On - Sab biotherapeutics inc - Page 1 : vimarsana.com

Short Interest in SAB Biotherapeutics, Inc (NASDAQ:SABSW) Increases By 600 0%

Short Interest in SAB Biotherapeutics, Inc (NASDAQ:SABSW) Increases By 600 0%
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

Biotherapeutics incSab biotherapeutics incGet free report

SAB Biotherapeutics (NASDAQ:SABS) Trading Down 1 7%

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report)’s stock price dropped 1.7% during mid-day trading on Thursday . The stock traded as low as $5.75 and last traded at $5.90. Approximately 4,952 shares traded hands during trading, a decline of 71% from the average daily volume of 17,130 shares. The stock had previously closed at […]

New yorkUnited statesSab biotherapeutics incFirst manhattanInstitutional family asset managementVanguard group incBiotherapeutics incPathstone family officeRenaissance technologiesGet free reportFamily officeFamily asset managementSab biotherapeuticsNasdaq sabs

SAB Biotherapeutics (NASDAQ:SABS) Stock Price Down 1 7%

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report)’s stock price fell 1.7% during mid-day trading on Thursday . The company traded as low as $5.75 and last traded at $5.90. 4,952 shares changed hands during trading, a decline of 71% from the average session volume of 17,130 shares. The stock had previously closed at $6.00. […]

Citadel advisorsSab biotherapeutics incRenaissance technologiesHightower advisorsMillennium managementBiotherapeutics incGet free reportTower advisorsState street corpStreet corpSab biotherapeuticsNasdaq sabs

FY2023 EPS Estimates for SAB Biotherapeutics, Inc (NASDAQ:SABS) Reduced by Analyst

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) – Equities researchers at HC Wainwright decreased their FY2023 earnings per share (EPS) estimates for shares of SAB Biotherapeutics in a note issued to investors on Monday, January 8th. HC Wainwright analyst E. White now anticipates that the company will earn ($4.03) per share for the year, down […]

Hightower advisorsRenaissance technologiesBiotherapeutics incMillennium managementSab biotherapeutics incCitadel advisorsFree reportGet free reportTower advisorsState street corpStreet corpSab biotherapeuticsNasdaq sabsEarnings estimatesHc wainwright

SAB Biotherapeutics, Inc (NASDAQ:SABSW) Short Interest Down 71 7% in November

SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) saw a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 1,300 shares, a drop of 71.7% from the November 15th total of 4,600 shares. Based on an average daily trading volume, of 4,200 shares, the days-to-cover […]

Sab biotherapeutics incBiotherapeutics incBiotherapeutics company profileGet free reportSab biotherapeuticsNasdaq sabsw